FDA Considers BLA for Pertuzumab Biosimilar HLX11 in Breast Cancer
FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer.
Related Articles
Blood-Based Test May Help Increase Colorectal Cancer Screening Rates
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Intro to AYA Patients, Survivors, and Substance Use
Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited support, and coping mechanisms, necessitating targeted prevention.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition
Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance…
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its prior HER2-low indication.
CD22-Directed CAR-T Therapy Provides Durable Remission and Long-Term Survival in Large B-Cell Lymphoma
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3…
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Arce-Gallego et al. integrate next-generation sequencing with a RAD51 immunofluorescence assay to assess HRR function in advanced prostate cancer. They link RAD51-IF scores to mutations in…
Healio seeks nominees for Disruptive Innovators in oncology/hematology
Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.Individuals who have changed the face of the specialty and pushed the status…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
RFK Jr. Nomination Advances to Senate Floor
The Senate Finance Committee voted today in favor of Robert F. Kennedy (RFK) Jr.’s nomination for Secretary of the Department of Health and Human Services,…